BR0003164A - Mutante ndv, vacinas viva e inativada contra doença de newcastle em aves, uso de um mutante ndv, e, processo de proteção de aves contra nd - Google Patents

Mutante ndv, vacinas viva e inativada contra doença de newcastle em aves, uso de um mutante ndv, e, processo de proteção de aves contra nd

Info

Publication number
BR0003164A
BR0003164A BR0003164-0A BR0003164A BR0003164A BR 0003164 A BR0003164 A BR 0003164A BR 0003164 A BR0003164 A BR 0003164A BR 0003164 A BR0003164 A BR 0003164A
Authority
BR
Brazil
Prior art keywords
birds
ndv mutant
mutant
ndv
live
Prior art date
Application number
BR0003164-0A
Other languages
English (en)
Other versions
BR0003164B1 (pt
Inventor
Teshome Mebatsion
Carla Christina Schrier
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Publication of BR0003164A publication Critical patent/BR0003164A/pt
Publication of BR0003164B1 publication Critical patent/BR0003164B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/17—Newcastle disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18161—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"MUTANTE NDV, VACINAS VIVA E INATIVADA CONTRA DOENçA DE NEWCASTLE EM AVES, USO DE UM MUTANTE NDV, E, PROCESSO DE PROTEçãO DE AVES CONTRA ND" A presente invenção provê um mutante NDV que é apropriado como um candidato de vacina para uma vacinação <MU>in ovo<MV>. O mutante expressa níveis reduzidos de proteína V e pode com segurança ser administrado e embriões de galinha antes da eclosão.
BRPI0003164-0A 1999-07-27 2000-07-26 mutante do vìrus da doença de newcastle (mutante ndv), vacinas viva e inativada contra doença de newcastle em aves, e uso de um mutante ndv. BR0003164B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99202467 1999-07-27
EP00201091 2000-03-27

Publications (2)

Publication Number Publication Date
BR0003164A true BR0003164A (pt) 2001-06-05
BR0003164B1 BR0003164B1 (pt) 2011-09-20

Family

ID=26072039

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0003164-0A BR0003164B1 (pt) 1999-07-27 2000-07-26 mutante do vìrus da doença de newcastle (mutante ndv), vacinas viva e inativada contra doença de newcastle em aves, e uso de um mutante ndv.

Country Status (11)

Country Link
US (1) US6699479B1 (pt)
JP (1) JP2001069970A (pt)
CN (1) CN1202126C (pt)
AT (1) ATE270708T1 (pt)
AU (1) AU775514B2 (pt)
BR (1) BR0003164B1 (pt)
CA (1) CA2312626A1 (pt)
DE (1) DE60011963T2 (pt)
ES (1) ES2223392T3 (pt)
HU (1) HU226036B1 (pt)
PL (1) PL198980B1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070085314A (ko) 2004-11-12 2007-08-27 바이엘 쉐링 파마 악티엔게젤샤프트 재조합 뉴캐슬 질환 바이러스
JPWO2007072916A1 (ja) * 2005-12-22 2009-06-04 財団法人化学及血清療法研究所 卵内接種用ワクチン
KR100801180B1 (ko) * 2006-09-26 2008-02-05 주식회사 고려비엔피 약독화된 재조합 뉴캐슬병 바이러스 및 이를 함유하는뉴캐슬병 백신
EP2085092A1 (en) 2008-01-29 2009-08-05 Bayer Schering Pharma Aktiengesellschaft Attenuated oncolytic paramyxoviruses encoding avian cytokines
CN108362875A (zh) * 2018-01-10 2018-08-03 华南农业大学 一种鉴别新城疫感染与免疫的间接elisa方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5427791A (en) 1992-08-05 1995-06-27 Regents Of The University Of Minnesota Embryonal vaccine against Newcastle disease
CA2181862C (en) 1995-08-01 2009-12-22 Carla Christina Schrier Mild newcastle disease virus vaccine
DK0770397T3 (da) * 1995-10-18 2004-08-09 Akzo Nobel Nv Newcastle disease viruskombinationsvaccine
EP0848956A1 (en) 1996-12-17 1998-06-24 Dimminaco Ag/Sa/Ltd. In ovo vaccination against Newcastle Disease
US6410023B1 (en) * 1997-05-23 2002-06-25 United States Of America Recombinant parainfluenza virus vaccines attenuated by deletion or ablation of a non-essential gene
EP0974660A1 (en) * 1998-06-19 2000-01-26 Stichting Instituut voor Dierhouderij en Diergezondheid (ID-DLO) Newcastle disease virus infectious clones, vaccines and diagnostic assays

Also Published As

Publication number Publication date
HUP0002908A2 (en) 2002-09-28
DE60011963D1 (de) 2004-08-12
CA2312626A1 (en) 2001-01-27
US6699479B1 (en) 2004-03-02
CN1202126C (zh) 2005-05-18
PL341724A1 (en) 2001-01-29
AU4876300A (en) 2001-02-01
JP2001069970A (ja) 2001-03-21
CN1281863A (zh) 2001-01-31
ATE270708T1 (de) 2004-07-15
PL198980B1 (pl) 2008-08-29
DE60011963T2 (de) 2005-08-25
AU775514B2 (en) 2004-08-05
ES2223392T3 (es) 2005-03-01
HU0002908D0 (en) 2000-09-28
HU226036B1 (en) 2008-03-28
BR0003164B1 (pt) 2011-09-20

Similar Documents

Publication Publication Date Title
BR9605153A (pt) Vacina de combinação para uso na proteção de galináceos contra a doença de newcastle kit de vacinação para imunizar galináceos contra a doença de newcastle e processo para a prevenção da doença de newcastle em galináceos
ATE255419T1 (de) Für den vogelembryo geeignete multivalente impfstoffe
ES2808827T3 (es) Respuesta inmune mejorada en especies aviares
AR044235A2 (es) Uso de una composicion que comprende merozoitos de eimeria vivos
PT650733E (pt) Vacina in ovo viva atenuada
BR0003164A (pt) Mutante ndv, vacinas viva e inativada contra doença de newcastle em aves, uso de um mutante ndv, e, processo de proteção de aves contra nd
BR0000190A (pt) Reovìrus de ave, processos para a preparação do mesmo, para controlar condições de doença que resultem de uma infecção de reovìrus de ave em aves domésticas e para a preparação de uma vacina para o uso na proteção de aves domésticas contra condições de doença que resultem de uma infecção de reovìrus de ave, e, vacina para o uso na proteção de aves domésticas.
BRPI0410332A (pt) vacina aviária de e. coli para proteção contra colibacilose
RU2011104201A (ru) Вакцины против инфекционного бронхита, полученные из ib-qх-подобных штаммов
ES2224294T3 (es) Vacunacion in ovo contra la enfermedad de newcastle.
BR0108735A (pt) Proteção in ovo contra bronquite infecciosa
BR0314378A (pt) Vacinas contendo vìrus envolvidos na sìndrome da má-absorção em aves e métodos para sua administração
AR003003A1 (es) Virus de la enfermedad de marek, una vacuna para la proteccion de aves de corral que contiene dicho virus y metodo para cultivarlo.
Cook et al. Use of an infectious bronchitis virus and Escherichia coli model infection to assess the ability to vaccinate successfully against infectious bronchitis in the presence of maternally‐derived immunity
BR0314349A (pt) Astrovìrus tipo 2 de galinha (castv-2), cultura de células, vacina para uso na proteção de aves domésticas contra doenças causadas pela infecção por astrovìrus aviário, e, métodos para a preparação de material antìgeno de castv-2, para a preparação de uma vacina e para a proteção de aves domésticas, em particular galinhas, contra doença causada pela infecção por astrovìrus aviário
ES2061165T3 (es) Vacuna para la proteccion de las aves de corral frente a la enfermedad de marek.
AR007611A1 (es) Linea celular de pollo infectada con virus de la enfermedad de marek perdurable, metodo para producir la linea celular, vacuna para aves y lineacelular de herpesvirus de la enfermedad de marek
BR9910438A (pt) Composições e processos para imunização de aves domésticas
Saravanabava et al. Effect of tuftsin on embryo vaccination with Newcastle disease virus vaccine
BR0115507A (pt) Métodos e vacinas para provisão de proteção in ovo contra rinotraqueìte de peru
AR035694A1 (es) Procedimiento para preparar vitamina e, contruccion de acido nucleico, combinacion de construcciones de acido nucleico, procedimiento para preparar organismos geneticamente modificados, uso de estos ultimos y uso de acidos nucleicos, construcciones de estos y combinaciones de construcciones en dicho
BR0102776A (pt) Mutante ibdv, vacina para uso na proteção de aves domésticas contra doença causada por infecção por ibdv, uso de um mutante ibdv, e, método para a proteção de aves domésticas contra doença causada por infecção por ibdv
ZA200101583B (en) Chicken anaemia viruses of low pathogenicity.
CA3147040A1 (en) Method for vaccinating avians against reovirus
Reagan et al. Response of young rabbits to infectious bronchitis virus (Wachtel strain)

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 20/09/2011, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE AS 13A, 14A E 15A ANUIDADES.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.